Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
These include semaglutide, the same medicine in Ozempic, which is called Wegovy
Information about Massachusetts Top cities in Massachusetts GLP-1 prescription in Boston GLP-1 prescription in South Boston GLP-1 prescription in Worcester GLP-1 prescription in Tatnuck GLP-1 prescription in Springfield GLP-1 prescription in East Springfield GLP-1 prescription in Brightwood GLP-1 prescription in Cambridge GLP-1 prescription in Lowell GLP-1 prescription in South Lowell GLP-1 prescription in Brockton GLP-1 prescription in New Bedford GLP-1 prescription in Quincy GLP-1 prescription in Lynn GLP-1 prescription in Dorchester GLP-1 prescription in West Lynn GLP-1 prescription in East Lynn GLP-1 prescription in Fall River GLP-1 prescription in North Fall River GLP-1 prescription in Newton GLP-1 prescription in Newtown GLP-1 prescription in Somerville GLP-1 prescription in Lawrence GLP-1 prescription in West Somerville Nearby states GLP-1 prescription in Rhode Island GLP-1 prescription in Connecticut GLP-1 prescription in New Hampshire GLP-1 prescription in Vermont GLP-1 prescription in New York GLP-1 prescription in Maine Frequently asked questions Do I need a prescription to get GLP-1 in Massachusetts
Seek urgent or emergency medical care for difficulty breathing, swelling of the face or throat, fainting, a severe allergic reaction or another potentially life-threatening symptom
What we know: GI side effects are common but typically improve after 36 months No deaths or major safety signals through 80104 weeks across two large trials Metabolic improvements (glucose, blood pressure, lipids) are substantial and sustained Discontinuation rate: 11.3% in general obesity population (TRIUMPH-1) better than initially feared from TRIUMPH-4's 18.2% 104-week extension shows continued weight loss to 30.3% no plateau at 80 weeks What we don't know: Full 2-year safety dataset (pending publication) Whether dysesthesia resolves or persists long-term Cardiovascular outcomes (trial ongoing) Weight regain trajectory after stopping Very rare adverse events requiring broader use to detect The bottom line: Retatrutide offers superior weight loss compared to existing medications and TRIUMPH-1's 11.3% discontinuation rate suggests the tolerability picture is better than TRIUMPH-4's osteoarthritis cohort implied
